Skip to main content

Table 3 Comparison of the leading two series study of patients in Western and Eastern countries with middle to lower third rectal adenocarcinoma, receiving trans-anal total mesorectal excision assisted by single port laparoscopic surgery

From: Neoadjuvant concurrent chemoradiotherapy followed by transanal total mesorectal excision assisted by single-port laparoscopic surgery for low-lying rectal adenocarcinoma: a single center study

 

Meillat et al.

The present study

P value

Follow-up intervals

1/2012–4/2015

12/2015-12/2018

 

Case numbers

41

23

 

Age

64

63

N/A

Sex

  

0.459***

 Male

27 (65.85%)

13 (56.52%)

 

 Female

14 (34.15%)

10 (43.48%)

 

BMI

24

23

N/A

Neoadjuvant CCRT

30/41 (73.17%)

23/23 (100.00%)

0.005**

Operative time (min)

358

366

N/A

Location of single port

   

 Ileostomy site

100%

100%

1.000**

Mobilization of splenic flexure

6/41 (14.63%)

19/23 (82.61%)

< 0.001**

Conversion

1/41 (2.44%)

1/23 (4.35%)

0.851*

Complication

10/41 (24.39%)

5/23 (21.74%)

0.815*

Type of anastomosis

  

< 0.001***

 Hand-sewn

41/41 (100.00%)

14/23 (60.87%)

 

 Stapled

0 (0.00%)

9/23 (39.13%)

 

Lymph nodes harvested

13

15

N/A

Pathologic T stages

  

< 0.001***

 ypT0

11 (26.83%)

5 (21.74%)

 

 ypT1

4 (9.76%)

5 (21.74%)

 

 ypT2

11 (26.83%)

9 (39.13%)

 

 ypT3

15 (36.59%)

4 (17.39%)

 

Pathologic N stages

  

< 0.001***

 ypN0

10 (23.39%)

19 (82.61%)

 

 ypN1

31 (75.61%)

4 (17.39%)

 

Distal margin status

  

< 0.001*

 R0

38 (92.68%)

23 (100.00)

 

 R1

3 (7.32%)

0 (0.00)

 

Inter-sphincteric resection

15/41 (36.59%)

14/23 (60.87%)

< 0.044**

Length of hospital stays (days)

10

8.4

N/A

  1. N/A not available, BMI body mass index, CCRT concurrent chemoradiotherapy
  2. *Fisher’s exact test
  3. **Student’s t test
  4. ***Chi-squared test